A γ-Tocopherol–Rich Mixture of Tocopherols Inhibits Colon Inflammation and Carcinogenesis in Azoxymethane and Dextran Sulfate Sodium–Treated Mice

Jihyeung Ju,1 Xingpei Hao,1 Mao-Jung Lee,1 Joshua D. Lambert,1 Gang Lu,1 Hang Xiao,1 Harold L. Newmark1 and Chung S. Yang1,2

Abstract We investigated the effects of a γ-tocopherol–rich mixture of tocopherols (γ-TmT, containing 57% γ-T, 24% δ-T, and 13% α-T) on colon carcinogenesis in azoxymethane (AOM)/dextran sulfate sodium (DSS)–treated mice. In experiment 1, 6-week-old male CF-1 mice were given a dose of AOM (10 mg/kg body weight, i.p.), and 1 week later, 1.5% DSS in drinking water for 1 week. The mice were maintained on either a γ-TmT (0.3%)–enriched or a standard AIN93M diet, starting 1 week before the AOM injection, until the termination of experiment. In the AOM/DSS–treated mice, dietary γ-TmT treatment resulted in a significantly lower colon inflammation index (52% of the control) on day 7 and number of colon adenomas (9% of the control) on week 7. γ-TmT treatment also resulted in higher apoptotic index in adenomas, lower prostaglandin E2, leukotriene B4, and nitrotyrosine levels in the colon, and lower prostaglandin E2, leukotriene B4, and 8-isoprostane levels in the plasma on week 7. Some of the decreases were observed even on day 7. In experiment 2 with AOM/DSS–treated mice sacrificed on week 21, dietary 0.17% or 0.3% γ-TmT treatment, starting 1 week before the AOM injection, significantly inhibited adenocarcinoma and adenoma formation in the colon (to 17–33% of the control). Dietary 0.3% γ-TmT that was initiated after DSS treatment also exhibited a similar inhibitory activity. The present study showed that γ-TmT effectively inhibited colon carcinogenesis in AOM/DSS–treated mice, and the inhibition may be due to the apoptosis-inducing, anti-inflammatory, antioxidative, and reactive nitrogen species–trapping activities of tocopherols.

Tocopherols are a family of phenolic compounds, each containing a chromanol ring system and a 16-carbon phytyl tail. These lipophilic compounds are synthesized by plants to serve as free radical scavengers (i.e., chain-breaking antioxidants) and are an important group of dietary antioxidants for humans (1, 2). γ-Tocopherol (γ-T) and α-tocopherol (α-T) are the major dietary tocopherols present in vegetable oils, such as oils from soybean, corn, and cottonseeds and nuts (3, 4). α-T is trimethylated at the 5-, 7-, and 8-positions of the chroman ring, whereas γ-T is dimethylated at the 7- and 8-positions.
Higher blood levels of $\gamma$-T have been correlated with lower risk of prostate cancer in two nested case-control studies (CLUE I and CLUE II; ref. 10), but such an association has not been observed in the Physician’s Healthy Study (11). In a nested-control study on Japanese Americans in Hawaii, higher serum $\gamma$-T levels have been nonsignificantly associated with lower prostate cancer risk and significantly associated with lower risk for cancers of the upper aerodigestive tract (12). Several studies have indicated that, compared with $\alpha$-T, $\gamma$-T is far more effective at inhibiting cyclooxygenase (13) activity, pro-inflammatory eicosanoids formation, inflammatory damage, and sphingolipid synthesis (14–17), at trapping reactive nitrogen species (18) and at increasing peroxisome proliferator-activated receptor-$\gamma$ expression (19, 20). $\gamma$-T has also been shown to be more effective than $\alpha$-T at inhibiting the growth of colon, breast, prostate, and lung cancer cells in culture (17, 21–24). There is, however, insufficient information on the effect of tocopherols on carcinogenesis in animal models. Most studies have been conducted with $\alpha$-T, the classic vitamin E, but the effects are either weak or inconsistent. For example, out of 10 studies on $\alpha$-T and colon tumorigenesis, 8 have shown no effect (25–32), 1 has shown an inhibitory effect (33), and 1 has shown an enhancement effect (34). Of five studies on $\alpha$-T and mammary tumorigenesis, four studies have shown a protective effect (30, 35–37), but one study has shown no effect (38).

Recently, we showed that dietary treatment with a $\gamma$-T–rich mixture of tocopherols ($\gamma$-TmT; 0.1% in diet) significantly inhibited azoxymethane (AOM)–induced colon aberrant crypt foci formation (39) and $N$-methyl-$N$-nitrosourea–induced mammary tumorigenesis in rats (40). $\gamma$-TmT is a commercially available by-product in the refining of edible vegetable oil. Dietary supplementation with this tocopherol mixture may be beneficial, especially in a population that has inadequate...
dietary intake of tocopherols. It is, therefore, important to have a more thorough understanding of the cancer-preventive activities of this mixture of tocopherols.

In the present work, we investigated the effects of this γ-TmT preparation on colon carcinogenesis in mice that received treatment with AOM and dextran sulfate sodium (DSS). DSS is known to produce colonic inflammation (41) and promote colon carcinogenesis (42). This mouse model enabled us to also investigate the effects of the treatment on colonic inflammation and related mechanisms.

Materials and Methods

Animal experiments

All animal experiments will be done under protocol no. 02-027 approved by the Institutional Animal Care and Use Committee at Rutgers University. In experiment 1, male CF-1 mice at 6 wk of age (Charles River Laboratories) were given a dose of AOM (10 mg/kg body weight, i.p.) or the vehicle (sterile saline). One week later, they were given 1.5% DSS (molecular weight of 36,000-50,000, ICN Biochemicals, Inc.) in drinking water for 1 wk. The mice were maintained on either a γ-TmT–enriched diet (0.3% in the diet) or AIN93M diet, starting 1 wk before the AOM injection (from 5 wk of age), until the experiment was terminated at 3 d, 7 d, or 7 wk after the DSS treatment (referred to as day 3, day 7, and week 7, respectively). The γ-TmT–enriched diet was formulated by adding 0.3% of γ-TmT to the semipurified AIN93M diet (Research Diets, Inc.). The γ-TmT used was a mixture containing 57% γ-T, 24% δ-T, 13% α-T, and 0.5% β-T (Cognis Corporation). Body weights, food and fluid consumption, and general health status were monitored weekly. For terminating the experiment, mice were sacrificed by CO2 asphyxia–consumption, and general health status were monitored weekly. At the end of experiment, mice were given 1.5% DSS in drinking water for 1 wk. The mice were maintained on either a γ-TmT–enriched diet (0.3% in the diet) or AIN93M diet, starting 1 wk before the AOM injection (from 5 wk of age), until the experiment was terminated at 3 d, 7 d, or 7 wk after the DSS treatment (referred to as day 3, day 7, and week 7, respectively). The γ-TmT–enriched diet was formulated by adding 0.3% of γ-TmT to the semipurified AIN93M diet (Research Diets, Inc.). The γ-TmT used was a mixture containing 57% γ-T, 24% δ-T, 13% α-T, and 0.5% β-T (Cognis Corporation). Body weights, food and fluid consumption, and general health status were monitored weekly. For terminating the experiment, mice were sacrificed by CO2 asphyxia–consumption, and general health status were monitored weekly. At the end of experiment, mice were given 1.5% DSS in drinking water for 1 wk. The mice were maintained on either a γ-TmT–enriched diet (0.3% in the diet) or AIN93M diet, starting 1 wk before the AOM injection (from 5 wk of age), until the experiment was terminated at 21 wk after the DSS treatment. In another group, 0.3% γ-TmT treatment was initiated after the 1 wk DSS treatment. Body weights, food, and fluid consumption, and general health status were monitored weekly. At the end of experiment, mice were harvested by CO2 asphyxia. Blood and tissues were harvested and stored as described above.

Histopathological and immunohisto pathological analyses

The formalin-fixed colon tissues from AOM/DSS–treated mice (sacrificed at week 7) were stained with 0.2% methylene blue solution for 3 to 5 min to visualize small colon polyps. The stained polyps and tumors were then dissected with surrounding normal colon tissues, paraffin-embedded, and sectioned serially at 4-μm thickness. All of the individual tumors and polyps were evaluated histopathologically in two H&E–stained sections (sections 1 and 10) per tumor. Histopathologically confirmed tumors were then classified into three categories—colon adenomas with mild, moderate, and severe dysplasia. Colonic neoplasms and dysplasia were diagnosed according to the typical criteria described previously (43, 44). The visible colon tumors from the AOM/DSS–treated mice sacrificed at week 21 were similarly dissected and evaluated histopathologically.

In two H&E-stained sections of the colon from AOM/DSS– or DSS–treated mice, sacrificed at 3 and 7 days after the DSS treatment, the inflammation index was determined. The inflammation index was the sum of scores of four individual inflammatory parameters: inflammation severity, ulceration, inflammation area involved, and hyperplasia and dysplasia (45, 46). The inflammation severity was scored as 0 (normal colonic mucosa), 1 (mild inflammation: either focal or widely separated multifocal inflammation limited to the basal one third of the mucosa with lost crypts), 2 (moderate inflammation: either multifocal or locally extensive inflammation and/or fibrosis up to two third of the crypts), or 3 (severe inflammation: mucosal ulcers with monocytes and polymorphonuclear leukocytes infiltrated into the mucosa, submucosa, muscularis propria and/or subserosa). The ulceration was scored as 0 (absent) or 1 (present). Ulceration was defined as an area of mucosa where the epithelial lining was missing. The inflammation area, which accounts for 0%, 1%, to 25%, 26-50%, 51-75%, or 76-100% of the surface area examined, was scored as 0, 1, 2, 3, or 4, respectively. Hyperplasia and dysplasia were scored as 0 (normal), 1 (mild hyperplasia: epithelial cells lined normally, but crypts 2 to 4 times thicker than normal crypts), 2 (low-grade dysplasia: 2 to 4 times thicker epithelium, hyperchromatic cells, fewer goblet cells, and scattered crypts developing an arborizing pattern), or 3 (high-grade dysplasia: >4 times thicker epithelium, hyperchromasia, few or no goblet cells, highly mitotic cells in the crypts with arborizing pattern, and crypts extended to muscularis mucosa or submucosa).

For immunohistochemistry, tissue sections were deparaffinized in xylene and rehydrated in distilled water, and the endogenous peroxidase was quenched in 0.3% hydrogen peroxide in methanol for 30 min. Subsequently, sections were subjected to antigen retrieval by heating the slides in sodium citrate buffer (0.01 mol/L, pH 6.0) in a pressure cooker for 3 min after reaching full pressure. Sections were then blocked for 1 h at room temperature in PBS containing 3% normal horse or goat serum. The sections were then immunostained with anti–cleaved caspase-3 (1: 200, Cell Signaling) antibodies overnight at room temperature. The antibodies were diluted in 10% goat or horse serum. The sections were rinsed in PBS and incubated with a biotinylated secondary antibody and subsequently incubated in Vectorstain Elite ABC reagent for 30 min, and 3,3′-diaminobenzidine (Vector Laboratories) was used as the chromogen. Sections were then counterstained with hematoxylin for 3 min with hematoxylin (Sigma) and mounted with Permount. Apoptotic cells were identified by staining with antibodies against cleaved caspase-3. Quantification of the number of total cells and cleaved caspase-3–positive cells in adenomas was done by using the Image-Pro Plus system as described previously (47). Apoptotic indexes were then expressed as the percentage of positive cells in total adenoma cells counted.

Analysis of tocopherols by high-performance liquid chromatography

The procedure for the determination of tocopherol levels in plasma was described previously (48). The methods was further improved and used for the determination of tissue and fecal levels of tocopherols and their metabolites. In brief, plasma sample (10 μL) was mixed with 140 μL ethanol and 150 μL ethanol. After homogenization, the supernatant was extracted with 1 mL hexane twice. For colon and fecal samples, 10 mg of sample were mixed with 140 μL deionized water and 150 μL ethan 1 mL hexane twice. For colon and fecal samples, 10 mg of sample were mixed with 140 μL deionized water and 150 μL ethanol. After homogenization, the supernatant was extracted with 1 mL hexane twice. The material in the dried hexane extract was re-dissolved in 100 μL ethanol and then injected onto high-performance liquid chromatography. For high-performance liquid chromatography analysis, a Supelcosil LC-18 reversed-phase column (150 × 4.6 mm; 5 μm particle size) was used. For the analysis of δ-, γ-, and α-tocopherols, an isocratic mobile phase of 82% ethanol in water containing 20 mmol/L ammonium acetate (pH 4.4) was used at a flow rate of 1.2 mL/min. The eluant was monitored with an ESA 5600A
Coulometric electrode array system (CEAS, ESA, Inc.) with potentials set at 200, 300, 500, and 700 mV. We have previously established a "standard plasma," with its tocopherol concentrations determined with standard curves constructed from standards of pure α-, γ-, and δ-tocopherols from the Center for Disease Control and Prevention (Atlanta, GA; ref. 48). The tocopherol concentrations in mouse plasma and tissues were determined by comparison with the peak heights of the standard plasma. Because the δ-T level in the standard plasma was low, γ-T in the standard was used as a surrogate for δ-T. We have established that the electrochemical responses of γ-T and δ-T are same.

**Enzyme immunoassay**

Procedures for prostaglandin E\(_2\) (PGE\(_2\)) and leukotriene B\(_4\) (LTB\(_4\)) enzyme immunoassay were the same as previously described (49). In brief, frozen colon tissues were placed into ice-cold T-PER tissue protein extraction buffer (Pierce Biotechnology) containing protease inhibitor cocktails (Sigma), indomethacin (a cyclooxygenase inhibitor, Cayman Chemical), and nordihydroguaiaretic acid (a lipoxigenase inhibitor, Sigma) and then homogenized using Polytron (Brinkmann Instruments Co.). After centrifugation for 10 min at 12,000 × g, the supernatants were retained as colon homogenates. Levels of nitrotyrosine and these levels were significantly increased by the γ-TmT treatment (0.3% in the diet) on general health and tocopherol levels in the plasma and tissues of AOM/DSS–treated mice (experiment 1).

**Results**

**Effects of dietary γ-TmT treatment on general health and tocopherol levels in the plasma and tissues of AOM/DSS–treated mice (experiment 1)**

The body weights of AOM/DSS–treated mice on γ-TmT–enriched AIN93M diet were similar to those of the control group (on AIN93M diet) throughout the experiment. The γ-TmT–treated mice looked healthy throughout the experiment and no signs of toxicity were observed. The liver weights of the γ-TmT–treated mice on week 7 did not differ from those in the control mice. Plasma alanine aminotransferase levels were not affected by γ-TmT treatment.

Some typical chromatograms of tocopherol analysis are shown in Fig. 1B. The effect of γ-TmT treatment (experiment 1) on plasma levels of tocopherols was examined at three time points (Fig. 1C). The major tocopherol found in the plasma of the control mice was α-T (∼12 μmol/L). The γ-TmT treatment did not significantly change the plasma α-T levels but significantly increased the plasma levels of γ-T (∼23-fold) and δ-T (∼37-fold). The effect of treatment with γ-TmT on colonic and fecal levels of tocopherols was examined at week 7. In the colon homogenates of the control mouse (Fig. 1D), δ-T and γ-T levels (both at ∼28 μmol/kg) were much higher than α-T levels (∼12 μmol/kg) and the γ-TmT treatment significantly increased levels of δ-T (30-fold) and γ-T (6-fold) but did affect the α-T levels. The feces had high levels of α-T, γ-T, and δ-T (93, 69, and 13 μmol/kg, respectively; Fig. 1E), and these levels were significantly increased by the γ-TmT treatment (4-, 7-, and 16-fold over the control, respectively). Several unknown peaks between 14 and 18 min were observed in the high-performance liquid chromatography analysis of the colon samples from γ-TmT–treated mice (Fig. 1B), but not in those of the control mice. Several peaks between 22 and 45 min were also observed in the analysis of the fecal samples from γ-TmT–treated mice, but not in those of the control mice (data not shown).

**Effect of γ-TmT on colon adenoma formation and apoptosis**

In experiment 1, the AOM/DSS–treated mice on the AIN93M diet had 6.5 ± 2.0 tumors per mouse in the colon,
and dietary treatment with \( \gamma \)-TmT resulted in a significantly lower number of colon tumors (0.6 ± 0.3; \( P < 0.05 \); Fig. 2).

All of the macroscopic tumors (>1 mm in diameter) were found in the middle and distal regions of colons. All of the tumors were histopathologically characterized as adenomas, mostly tubular adenomas. We subsequently classified the adenomas into three different categories: mild, moderate, and severe dysplasia (accounting for 34% and 54%, respectively). The \( \gamma \)-TmT–treated group had fewer colon adenomas than the control group, and those with mild, moderate, and severe dysplasia were lower by 63%, 95%, and 94%, respectively. Most of the methylene blue–stained small polyps (<1 mm in diameter) were identified as a gut-associated lymphoid tissue.

To determine the effect of \( \gamma \)-TmT on apoptosis, adenomas from \( \gamma \)-TmT–treated group and the control group were analyzed for apoptosis by immunohistochemistry with anti–cleaved caspase-3 antibody (Fig. 3E, F). Cleaved caspase-3–positive cells displaying nuclear staining were observed in adenomas but rarely in the normal mucosa. Apoptotic index was expressed as the percentage of cleaved caspase-3 positively stained cells among total cells in adenomas observed in each tissue section.
The γ-TmT–treated group had a significantly higher apoptotic index (6.3% ± 1.7; 6 adenomas analyzed) than the control group (3.6% ± 0.4; 20 adenomas analyzed; P = 0.03). γ-TmT treatment did not cause any appreciable increase of cleaved caspase-3–positive cells in normal mucosa.

**Effect of γ-TmT on colonic inflammation**

In AOM/DSS–treated mice, the inflammation seemed to progress from day 3 to day 7. The γ-TmT treatment resulted in a lower inflammation index in the colon in mice sacrificed on day 7 (52% of the control; P < 0.05; Table 1; Fig. 3G, H), but not those sacrificed on day 3. Among individual inflammatory parameters, the decrease in the grade for hyperplasia and dysplasia was most prominent (P < 0.05). In the mice that received DSS only, the inflammation index on day 7, however, was significantly lower than that on day 3, apparently due to recovery from the DSS-induced damage. In the mice that only received DSS, γ-TmT treatment did not decrease the inflammation index on days 3 and 7.

**Effects of γ-TmT on plasma and colonic PGE2 and LTB4 levels**

The plasma levels of PGE2 and LTB4 in AOM/DSS–treated mice on days 3 and 7 were 2- to 3-fold higher than in mice treated with DSS only (P ≤ 0.05, Fig. 4A) and 26- to 31-fold higher than those at earlier time points, and γ-TmT treatment resulted in significantly lower levels (9% of the control; P < 0.05), but the effect was not seen at earlier time points (Fig. 4B). Tumor samples were processed for histologic analyses and were not suitable for biochemical analyses.

**Effects of γ-TmT on plasma 8-isoprostane and colonic nitrotyrosine levels**

The plasma levels of 8-isoprostane in AOM/DSS–treated mice on days 3 and 7 were higher than those in the corresponding DSS-treated mice (P < 0.01; Fig. 4A) and much higher than those in mice that did not receive any treatment (with value of 6.9 ± 0.8 pg/mL; n = 3; P < 0.03). The plasma 8-isoprostane levels of the AOM/DSS–treated mice on week 7 were much higher than those at earlier time points, and γ-TmT treatment resulted in significantly lower levels (9% of the control; P < 0.05). The γ-TmT treatment also resulted in lower levels in the AOM/DSS–treated mice on day 7 (53% of the control; P < 0.05). The 8-isoprostane lowering effect by γ-TmT was not statistically significant in mice that received DSS only. Nitrotyrosine levels were determined in nontumorous colon homogenates of the AOM/DSS–treated mice on week 7, PGE2 and LTB4 levels were also lower in the γ-TmT–treated group than those in the control group (57% and 48% of the control, respectively; P < 0.05), but the effect was not seen at earlier time points (Fig. 4B). Tumor samples were processed for histologic analyses and were not suitable for biochemical analyses.

**Effects of γ-TmT on colon adenocarcinoma formation and other parameters in AOM/DSS–treated mice (experiment 2)**

To investigate the effect of γ-TmT on colon adenocarcinoma formation, we conducted a longer experiment, in which male CF-1 mice were treated with the 0.3% γ-TmT, 0.17% γ-TmT, or 0% γ-TmT (control) diets for 8 weeks, and were sacrificed on week 7. The results are summarized in Table 1. The γ-TmT–treated group had a significantly lower grade for dysplasia (15–48% of the control; P < 0.05) on day 7 and week 7. The inflammation index (6.3% ± 1.7; 6 adenomas analyzed) was significantly lower than that on day 3, apparently due to recovery from the DSS-induced damage. In the mice that only received DSS, γ-TmT treatment did not decrease the inflammation index on days 3 and 7.

### Table 1. Effects of dietary treatment with γ-TmT on colonic inflammation in AOM/DSS–treated or DSS-treated CF-1 mice

<table>
<thead>
<tr>
<th>Group (n)</th>
<th>Severity</th>
<th>Ulceration</th>
<th>Area involved</th>
<th>Hyperplasia and dysplasia</th>
<th>Inflammation index</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 d after DSS treatment (day 3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AOM/DSS–control (10)</td>
<td>1.7 ± 0.3</td>
<td>1.4 ± 0.6</td>
<td>0.8 ± 0.3</td>
<td>0.3 ± 0.2</td>
<td>4.2 ± 1.3</td>
</tr>
<tr>
<td>AOM/DSS–γ-TmT (10)</td>
<td>2.3 ± 0.3</td>
<td>2.8 ± 0.9</td>
<td>1.3 ± 0.4</td>
<td>0.4 ± 0.3</td>
<td>6.6 ± 1.3</td>
</tr>
<tr>
<td>DSS-control (4)</td>
<td>1.8 ± 0.5</td>
<td>2.8 ± 0.6</td>
<td>1.0 ± 0</td>
<td>0.3 ± 0.3</td>
<td>5.8 ± 1.1</td>
</tr>
<tr>
<td>DSS–γ-TmT (5)</td>
<td>2.0 ± 0.5</td>
<td>2.0 ± 0.6</td>
<td>1.8 ± 0.8</td>
<td>0.8 ± 0.4</td>
<td>6.5 ± 2.0</td>
</tr>
<tr>
<td>7 d after DSS treatment (day 7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AOM/DSS–control (10)</td>
<td>1.9 ± 0.4</td>
<td>1.5 ± 0.4</td>
<td>1.1 ± 0.4</td>
<td>1.6 ± 0.3</td>
<td>6.1 ± 1.3</td>
</tr>
<tr>
<td>AOM/DSS–γ-TmT (10)</td>
<td>1.4 ± 0.3</td>
<td>0.7 ± 0.3</td>
<td>0.6 ± 0.2</td>
<td>0.5 ± 0.3</td>
<td>3.2 ± 1.0</td>
</tr>
<tr>
<td>DSS-control (3)</td>
<td>1.3 ± 0.9</td>
<td>0.3 ± 0.3</td>
<td>0.3 ± 0.3</td>
<td>0 ± 0</td>
<td>2.0 ± 1.5</td>
</tr>
<tr>
<td>DSS–γ-TmT (5)</td>
<td>2.3 ± 0.7</td>
<td>2.8 ± 1.4</td>
<td>1.0 ± 0.4</td>
<td>1.3 ± 0.4</td>
<td>7.3 ± 2.6</td>
</tr>
</tbody>
</table>

NOTE: The samples were from experiment 1. All the analyzable field of colons was sectioned and H&E stained, and two sections per colon were analyzed. The inflammation index was the sum of the individual scores for disease severity, ulceration, area of inflammatory involvement, and grade of hyperplasia and dysplasia. Values are mean ± SE per mouse.

*The value is different from that of AOM/DSS–treated group on day 3 (P < 0.01 by the two-tailed t test).
†The value is different from that of the control group on day 7 (P < 0.05 by the two-tailed t test).
‡The value is different from that of the control group on day 7 (P < 0.05 by the one-tailed t test).
§The value is different from that of the control group on day 3 (P = 0.09 by two-tailed t test; P < 0.05 by the one-tailed t test).
¶The value is different from that of AOM/DSS–treated group on day 7 (P < 0.05 by the two-tailed t test).
AIN93M diet until the experiment was terminated at 21 weeks after DSS treatment (experiment 2). In this experiment, we modified the AOM dosing scheme; the mice were given AOM (5 mg/kg body weight, i.p.) twice at 4 days interval. The control mice (AOM/DSS–treated mice on AIN93M diet) on week 21 had 2.4 ± 0.8 tumors per mouse in the colon, and 75% of the tumors were histopathologically identified as well-differentiated adenocarcinomas (1.8 ± 0.7 per mouse; Table 2). Dietary treatment with 0.3% and 0.17% γ-TmT, starting 1 week before the first AOM injection, resulted in significantly lower numbers of colon tumors (adenocarcinomas lowered by 83% and 67%, respectively). Dietary 0.3% γ-TmT treatment that was initiated after the 1 week DSS treatment also exhibited similar inhibitory activity (adenocarcinomas lowered by 78%).

The plasma levels of PGE2, LTB4, and 8-isoprostane in AOM/DSS–treated mice on week 21 were 2,150.8 ± 29.1, 2,021.0 ± 564.2, and 1,107.4 ± 97.3 pg/mL, respectively, and all three γ-TmT treatment groups resulted in significantly lower levels of PGE2 (to <1% of the control), LTB4 (to 19-24% of the control), and 8-isoprostane (to 1.1-2.3% of the control) in the plasma (P < 0.001; data not shown in Table 2). In nontumorous colon homogenates of the AOM/DSS–treated mice, PGE2, LTB4, and nitrotyrosine levels were also lower in the γ-TmT–treated groups than those in the control group (38-89% of the control; P < 0.05).

The effects of dietary γ-TmT treatments on plasma, liver, and colon levels of tocopherols were also examined. As expected, the major tocopherol found in the control mice was α-T. Both the 0.17% and 0.3% γ-TmT treatments significantly increased plasma levels of γ-T (5-fold of the control), δ-T (17- to 21-fold), and even α-T (~2-fold), but no clear dose-dependent increases were found. Hepatic levels of γ-T and δ-T, but not α-T, were significantly increased by the γ-TmT treatments. The γ-TmT treatments increased γ-T (24- to 29-fold) and δ-T (52- to 66-fold) in the colon; both tocopherols were in the concentration range of 10 to 13 μmol/kg in the γ-TmT–treated mice.

![Fig. 4. Effects of γ-TmT treatment on plasma or colonic levels of PGE2, LTB4, 8-isoprostane, and nitrotyrosine. A, PGE2, LTB4, and 8-isoprostane levels were determined in the plasma of AOM/DSS–treated mice (on day 3, day 7, and week 7) and DSS–treated mice (on days 3 and 7). B, PGE2, LTB4, and nitrotyrosine levels were determined in the colon (homogenates) of AOM/DSS–treated mice. Columns, mean of group (n = 9-10 per AOM/DSS–treated group; n = 4-5 per DSS–treated group); bars, SE. Different superscripts (a, b, c, d) indicate statistical difference among levels of AOM/DSS–treated mice (by one-way ANOVA; P < 0.05). Statistical difference between levels of the γ-TmT–treated and the respective control group: **, P < 0.05 by the two-tailed t-test; *, P < 0.05 by the one-tailed t-test (P = 0.07 by two-tailed t-test).](http://example.com/fig4.png)
than those in the AIN93M diet (γ-αTmT) significantly increased γ-αTmT against colon carcinogenesis. We found that γ-TmT inhibits colon carcinogenesis at the postinitiation stage. To our knowledge, this is the first report on the inhibitory activity of a mixed tocopherol preparation on colon inflammation and carcinogenesis. The inhibitory activity of γ-TmT against colon carcinogenesis found in the present study was as strong as the inhibitory activities of other chemopreventive agents, such as a cyclooxygenase-2 inhibitor (nimesulide), peroxisome proliferator-activated receptor ligands (triglitazone and bezafibrate), and a statin (pivastatin), in the AOM/DSS model (51, 52). This study is also the first study that reported the inhibitory activity against colon carcinogenesis. Jiang et al. (15) showed that there was a possible synergy between γ-T and δ-T observed in the colon, it is interesting to suggest that γ-T, δ-T, and the interaction between these tocopherols play important roles in the inhibitory effect against colon carcinogenesis. Jiang et al. (15) showed that there was a possible synergy between γ-T and δ-T in inhibiting the growth of prostate cancer cells. We have observed in our preliminary cell culture study using HT29 and HCT116 colon cancer cell lines that the treatment with γ-T or δ-T (at the concentration of 25-75 μmol/L δ-T or γ-T for 48-72 h) inhibited the growth of cell, whereas α-T was rather inactive.3

In this study, we characterized the coloninflammation process in the AOM/DSS model, and these results suggest that the pretreatment of AOM prevents the resolution of DSS-induced inflammation and further promotes hyperplasia and dysplasia (Table 1). Pro-inflammatory eicosanoids, PGE2 and LTB4, are implicated in both inflammation and carcinogenesis. We found that γ-TmT treatments resulted in significantly decreased levels of PGE2 and LTB4 in the plasma and the nontumorous colon tissue of the AOM/DSS–treated mice (Fig. 1D). Several metabolites were observed in the colon tissues (Fig. 1B) and feces; those could be products with degraded phytyl chain or nitrated γ-T or δ-T. All the metabolites need to be further identified.

### Discussion

The inhibitory activity of α-T on colon tumorigenesis is either weak or inconsistent in previous studies (25–32). γ-T has been shown to have stronger antioxidative and anti-inflammatory activities than α-T (2, 5, 6). It has also been shown to be more effective than α-T at inhibiting the growth of colon, breast, prostate, and lung cancer cells (17, 21–24). γ-T is, therefore, likely the major tocopherol of the mixture that conferred the inhibitory activity against colon carcinogenesis. It is also possible that the interaction of γ-T with other tocopherols produced the strong inhibitory activity of the mixture. Because of the high concentration of γ-T and δ-T observed in the colon, it is interesting to suggest that γ-T, δ-T, and the interaction between these tocopherols play important roles in the inhibitory effect against colon carcinogenesis. Jiang et al. (15) showed that there was a possible synergy between γ-T and δ-T in inhibiting the growth of prostate cancer cells. We have observed in our preliminary cell culture study using HT29 and HCT116 colon cancer cell lines that the treatment with γ-T or δ-T (at the concentration of 25-75 μmol/L δ-T or γ-T for 48-72 h) inhibited the growth of cell, whereas α-T was rather inactive.3

In this study, we characterized the coloninflammation process in the AOM/DSS model, and these results suggest that the pretreatment of AOM prevents the resolution of DSS-induced inflammation and further promotes hyperplasia and dysplasia (Table 1). Pro-inflammatory eicosanoids, PGE2 and LTB4, are implicated in both inflammation and carcinogenesis. We found that γ-TmT treatments resulted in significantly decreased levels of PGE2 and LTB4 in the plasma and the nontumorous colon tissue of the AOM/DSS–treated mice (Fig. 1D). Several metabolites were observed in the colon tissues (Fig. 1B) and feces; those could be products with degraded phytyl chain or nitrated γ-T or δ-T. All the metabolites need to be further identified.

### Table 2. Effects of dietary γ-TmT treatments on colon adenocarcinoma and adenoma formation in AOM/DSS–treated mice

<table>
<thead>
<tr>
<th>Group</th>
<th>Visible tumors</th>
<th>No./mouse</th>
<th>Adenocarcinomas</th>
<th>Adenomas</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>41.2 (7/17)</td>
<td>2.4 ± 0.8</td>
<td>1.8 ± 0.7</td>
<td>0.6 ± 0.3</td>
<td>2.4 ± 0.8</td>
</tr>
<tr>
<td>0.17% γ-TmT</td>
<td>15.8 (3/19)</td>
<td>0.6 ± 0.5</td>
<td>0.6 ± 0.5</td>
<td>0.1 ± 0.1</td>
<td>0.6 ± 0.5</td>
</tr>
<tr>
<td>0.3% γ-TmT</td>
<td>12.5 (2/16)</td>
<td>0.3 ± 0.2</td>
<td>0.3 ± 0.2†</td>
<td>0.1 ± 0.1†</td>
<td>0.3 ± 0.2†</td>
</tr>
<tr>
<td>Control → 0.3% γ-TmT</td>
<td>15.8 (3/19)</td>
<td>0.5 ± 0.3</td>
<td>0.4 ± 0.3*</td>
<td>0.1 ± 0.1†</td>
<td>0.5 ± 0.3†</td>
</tr>
</tbody>
</table>

NOTE: Results of experiment 2. The mice were maintained on the 0.17% γ-TmT, 0.3% γ-TmT, or AIN93M diet, starting 1 wk before the AOM injection (from 5 wk of age), until the experiment was terminated at 21 wk after the DSS treatment. The control → 0.3% γ-TmT group received 0.3% γ-TmT diet after the DSS treatment. Formalin-fixed visible tumors were dissected, embedded, sectioned, and H&E-stained for histopathological analysis. All of the visible tumors scored were histologically confirmed as adenomas or adenocarcinomas. Values are mean ± SE per mouse.

*P < 0.05 by one-tailed t test (P = 0.07-0.09 by two-tailed t test).
†P < 0.05 by the two-tailed t test.

3 Unpublished results.
2, cyclooxygenase-2, and 5-lipoxygenase) in the nontumorous colon homogenates, however, were not significantly affected by the γ-TmT treatment (data not shown). The biochemical analysis of nontumorous colon tissues should provide information on the preventive action of γ-TmT. The decreases in the PGE2 levels may be due to the inhibition of cyclooxygenase-2 activity by γ-T, as shown by Jiang et al. in lipopolysaccharide-stimulated macrophages and interleukin-1β-activated epithelial cells (15). Alternatively, the decreased levels of PGE2 and LTB4 are a consequence of the decreased inflammation or carcinogenesis. We found that the plasma levels of PGE2 and LTB4 in the AOM/DSS-treated mice were higher than in the mice treated with DSS only and much higher than in mice that did not receive any treatment (Fig. 4A), suggesting that DSS treatment elevates the levels of pro-inflammatory eicosanoids and the pretreatment with AOM further elevates the levels.

Tocopherols, as antioxidants, can scavenge reactive oxygen and nitrogen species. Isoprostanes are a family of eicosanoids that are produced by the random oxidation of phospholipids. 8-Isoprostane (8-isoPGF2α) is implicated as a causative mediator of pulmonary oxygen toxicity (54), and its level is elevated in heavy smokers (55). The plasma 8-isoprostane levels of the AOM/DSS-treated mice were higher than in the corresponding DSS-treated mice and markedly higher than in the mice that did not receive any treatment. The plasma 8-isoprostane levels of the AOM/DSS-treated mice on week 7 were much higher than those at earlier time points (Fig. 4A). The γ-TmT treatment resulted in significantly decreased 8-isoprostane levels on day 7, week 7, and week 21. These results suggest that oxidative stress is increased during tumorigenesis and it is inhibited by γ-TmT. Nitrosyrosine is a biomarker of NO-mediated protein modification and is commonly used to detect NO-mediated cellular damage. Colonic nitrosyrosine levels were markedly decreased in the γ-TmT-treated mice on day 7 and week 7 (Fig. 4B) and moderately decreased in the γ-TmT-treated mice on week 21, suggesting that the γ-TmT treatment inhibited nitrosative stress. The inhibition of protein nitration may be partially due to the NOX-trapping capability of γ-T, as previously shown in a rat model of zymosan-induced peritonitis (18) and in other experimental systems (56–59).

In summary, we showed that the dietary γ-TmT treatment (0.3% and 0.17% in AIN93M diet) significantly inhibited colon carcinogenesis in AOM/DSS-treated mice. We also systemically characterized the inflammation process in this model and showed the anti-inflammatory activity of γ-TmT. The inhibition may be due to the apoptosis-inducing, anti-inflammatory, antioxidant, and reactive nitrogen species–trapping activities of tocopherols, especially of γ-T and δ-T, which are present in rather higher concentration in the colon. γ-TmT is a byproduct in the refining of edible vegetable oil with different tocopherols at ratios similar to the human diet. It is readily available, nontoxic, and may have a great potential for future use in cancer prevention. The present results provide the preclinical data for translation to clinical trials for the prevention of colon cancer.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We thank Anna Lu and Afshieve Khan for their help in animal studies.

References

www.aacrjournals.org

Downloaded from cancerpreventionresearch.aacr.org on June 19, 2017. © 2009 American Association for Cancer Research.


A \( \gamma \)-Tocopherol–Rich Mixture of Tocopherols Inhibits Colon Inflammation and Carcinogenesis in Azoxymethane and Dextran Sulfate Sodium–Treated Mice


Updated version  Access the most recent version of this article at:
doi:10.1158/1940-6207.CAPR-08-0099

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.